F040 Vitiligo: Evidenced Based Medicine applied to Cases
DESCRIPTION
This session will focus on evidence based knowledge regarding vitiligo which has emerged from recent clinical trials and studies to elevate the treatment of patients. This will include recent data on what patients most want to know during visits and how to ensure that patient goals are met. We will also review via a case based approach how to treat challenging situations that arise in practice. There is also a focus on how dermatologists can serve to improve healthcare disparities that have arisen in the treatment of vitiligo
LEARNING OBJECTIVES
Recognize the importance of when vitiligo may rapidly spread for aggressive treatment
Summarize the new data available that dispels myths about treating vitiligo, so patients receive the best possible treatment
Discuss what is still unknown regarding vitiligo treatment and how to communicate with patients the information important to them for compassionate care
SCHEDULE
1:00 PM
Introduction
David Rosmarin, MD, FAAD
1:05 PM
Comorbidities
Viktoria Eleftheriadou, MD, PhD
1:15 PM
Skin cancer and vitiligo
Khaled Ezzedine, MD, PhD, IFAAD
1:25 PM
Management of stable vitiligo
Rebecca Vasquez, MD, FAAD
1:35 PM
Management of active vitiligo
Victor Huang, MD, FAAD
1:45 PM
Panel Discussion
2:00 PM
Patient perspective
2:10 PM
Pediatric vitiligo
Anshika Kaushik, MD, FAAD
2:20 PM
What's new in basic science and research
Julien Seneschal, MD, PhD
2:30 PM
How to most effectively use ruxolitinib cream
David Rosmarin, MD, FAAD
2:40 PM
Panel Discussion
DIRECTOR
David Rosmarin, MD, FAAD
SPEAKERS
Viktoria Eleftheriadou, MD, PhD
Khaled Ezzedine, MD, PhD, IFAAD
Priyanka Francis
Victor Huang, MD, FAAD
Anshika Kaushik, MD, FAAD
Julien Seneschal, MD, PhD
Rebecca Vasquez, MD, FAAD
DISCLOSURES
Viktoria Eleftheriadou, MD, PhD
No financial relationships exist with ineligible companies.
Khaled Ezzedine, MD, PhD, IFAAD
AbbVie – Advisory Board(Fees); BMS – Speaker(Honoraria); Eli Lilly – Speaker(Honoraria); Pfizer Inc. – Advisory Board(Fees); Pierre Fabre Dermatologie – Speaker(Honoraria);
Priyanka Francis
No financial relationships exist with ineligible companies.
Victor Huang, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Avita Medical – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Incyte – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding);
Anshika Kaushik, MD, FAAD
No financial relationships exist with ineligible companies.
David Rosmarin, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Abcuro, Inc. – Consultant(Honoraria); Almirall – Consultant (1099 relationship)(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Speaker(Honoraria); Arena Pharmaceuticals – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Celgene Corporation – Advisory Board(Honoraria), Speaker(Honoraria); Concert Pharmaceuticals – Consultant(Honoraria), Data Safety Monitoring Board(Honoraria); CSL Behring – Consultant(Honoraria); Dermavant Sciences – Advisory Board(Honoraria), Speaker(Honoraria); Dermira – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding), Other(Other Financial Benefit), Speaker(Honoraria); Janssen Biotech – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Merck & Co., Inc – Investigator(Grants/Research Funding); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); RAPT Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Revolo Therapeutics – Consultant(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant(Honoraria); UCB – Advisory Board(Honoraria); Viela Bio – Advisory Board(Honoraria); Zura Bio – Consultant (1099 relationship)(Honoraria);
Julien Seneschal, MD, PhD
No financial relationships exist with ineligible companies.
Rebecca Vasquez, MD, FAAD
Incyte – Consultant (1099 relationship)(Honoraria);